@article{7045d5a1c064443fb1bc3b46d8346042,
title = "Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule",
abstract = "no abstract",
keywords = "Aged, Antimetabolites, Antineoplastic, Azacitidine, Disease Progression, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Approval, Humans, Male, Myelodysplastic Syndromes, Time Factors, Aged, Antimetabolites, Antineoplastic, Azacitidine, Disease Progression, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Approval, Humans, Male, Myelodysplastic Syndromes, Time Factors",
author = "Voso, {Maria Teresa} and Luana Fianchi and Marianna Criscuolo and Marco Greco and Francesco D'Alo' and Stefan Hohaus and Livio Pagano and Giuseppe Leone",
year = "2012",
doi = "10.1016/j.leukres.2011.08.010",
language = "English",
volume = "36",
pages = "e15--e15--7",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
}